Skip to main content
OpenTrials
Completed

NCT Number: NCT04885582

The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation

Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today.

The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Health science University - Kayseri State Hospital

Kocasinan, Kayseri, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with liver transplantation and tested for HLA antigen (recipient - donor)

Exclusion criteria

  • patients who died early Patients whose HLA antigen is not checked

Treatment and study plan

HLA antigen results

Other

HLA-A, HLA-B, HLA-DR tissue matching results in both groups will be compared.

Primary outcomes

  1. Bliary complications

    Time frame: 2 years

    Biliary fistüla, biliary stenosis

Sponsors and collaborators

Lead sponsor

Inonu University

Other

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2020
First posted
May 13, 2021
Registry last updated
May 13, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.